Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 8/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL857295 | 0.87 | TLR4 (0.48) | TLR4ALDH1A1KMT2AMAPTKDM4E | |
| SCHEMBL8234310 | 0.82 | TLR4 (0.56) | TLR4ALDH1A1KMT2AMAPTLMNA | |
| SCHEMBL1198839 | 0.76 | CPB1 (0.42) | TLR4ALDH1A1MAPTTSHRHTT | |
| SCHEMBL989622 | 0.75 | — | — | |
| SCHEMBL3628762 | 0.75 | — | — | |
| SCHEMBL11065341 | 0.75 | TLR4 (0.40) | TLR4ALDH1A1KMT2AMAPTTSHR | |
| SCHEMBL1651765 | 0.75 | TLR4 (0.40) | TLR4SMN1; SMN2 | |
| SCHEMBL8904452 | 0.73 | TLR4 (0.69) | TLR4MAPT | |
| SCHEMBL11066052 | 0.73 | TSHR (0.33) | TLR4ALDH1A1MAPTTSHRHTT | |
| SCHEMBL10450947 | 0.72 | TLR4 (0.49) | TLR4ALDH1A1KMT2AMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963300-B1 | BENZOCHROMENE DERIVATIVES FOR USE IN LIQUID CRYSTAL MEDIA AND AS THERAPEUTIC ACTIVE SUBSTANCES | MERCK PATENT GMBH (DE) | 2012-08-22 | — | — | EP | disclosed |
| EP-1963298-B1 | Benzochromene derivatives | MERCK PATENT GMBH (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-7998541-B2 | Benzochromene derivatives for use in liquid crystal media and as therapeutic active substances | MERCK PATENT GMBH (DE) | 2011-08-16 | — | — | US | disclosed |
| US-7998541-B2 | Benzochromene derivatives for use in liquid crystal media and as therapeutic active substances | MERCK PATENT GMBH (DE) | 2011-08-16 | — | — | US | disclosed |
| US-7998541-B2 | Benzochromene derivatives for use in liquid crystal media and as therapeutic active substances | MERCK PATENT GMBH (DE) | 2011-08-16 | — | — | US | disclosed |
| US-7824745-B2 | Benzochromene derivatives | MERCK PATENT GMBH (DE) | 2010-11-02 | — | — | US | disclosed |
| US-7824745-B2 | Benzochromene derivatives | MERCK PATENT GMBH (DE) | 2010-11-02 | — | — | US | disclosed |
| US-7824745-B2 | Benzochromene derivatives | MERCK PATENT GMBH (DE) | 2010-11-02 | — | — | US | disclosed |
| US-20090247620-A1 | Benzochromene Derivatives for Use in Liquid Crystal Media and as Therapeutic Active Substances | MERCK PATENT GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
| US-20090247620-A1 | Benzochromene Derivatives for Use in Liquid Crystal Media and as Therapeutic Active Substances | MERCK PATENT GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
| US-20090247620-A1 | Benzochromene Derivatives for Use in Liquid Crystal Media and as Therapeutic Active Substances | MERCK PATENT GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
| US-20090023802-A1 | Benzochromene Derivatives | MERCK PATENT GMBH (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023802-A1 | Benzochromene Derivatives | MERCK PATENT GMBH (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023802-A1 | Benzochromene Derivatives | MERCK PATENT GMBH (DE) | 2009-01-22 | — | — | US | disclosed |
| WO-2007079842-A1 | BENZOCHROMENE DERIVATIVES FOR USE IN LIQUID CRYSTAL MEDIA AND AS THERAPEUTIC ACTIVE SUBSTANCES | MERCK PATENT GMBH (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247620-A1 | Benzochromene Derivatives for Use in Liquid Crystal Media and as Therapeutic Active Substances | LPO, SBDS, OCIAD1 | TLR4 833/4885ALDH1A1 1625/4885KMT2A 4533/4885 |
| US-20090023802-A1 | Benzochromene Derivatives | SBDS, CRY1, DDT | TLR4 498/4885ALDH1A1 676/4885KMT2A 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.